Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Stanley Medical Research Institute Clear all
Completed Phase 2 Interventional Results available

Systematic Evaluation of Antiviral Medication in Schizophrenia

NCT00514449
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Konasale Prasad
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

NCT00403247
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Capsule with folate, Vitamin B12 & pyridoxine, placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 2Phase 3 Interventional

Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

NCT01528839
View directory record Official record
Conditions
Bipolar Disorder
Interventions
L-Thyroxine, Placebo
Drug
Lead sponsor
Charite University, Berlin, Germany
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Kuvan in People With Schizophrenia and Schizoaffective Disorder

NCT01706965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Kuvan, Multivitamin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

NCT00854737
View directory record Official record
Conditions
Bipolar Disorder
Interventions
cytidine, omega-3 fatty acids, placebo
Dietary Supplement · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Belmont, Massachusetts • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

A Trial of SAMe for Treatment-Resistant Bipolar Depression

NCT00762268
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar Depression
Interventions
SAMe, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

NCT00227123
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
Interventions
quetiapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

Magnetic Seizure Therapy (MST) for Severe Mood Disorder

NCT00488748
View directory record Official record
Conditions
Depression
Interventions
Thymatron, Magstim Theta
Device
Lead sponsor
Sarah Lisanby
Other
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia

NCT01242371
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Probiotic Supplement, Identical-appearing Placebo
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Minocycline and Aspirin in the Treatment of Bipolar Depression

NCT01429272
View directory record Official record
Conditions
Bipolar Disorder Depression
Interventions
Minocycline, Aspirin, placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Wichita, Kansas • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 8, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional

Low Field Magnetic Stimulation Treatment for Bipolar Depression

NCT00217217
View directory record Official record
Conditions
Bipolar Depression, Bipolar Disorder, Depression
Interventions
Echo-Planar Magnetic Resonance Imaging (EP-MRSI)
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

NCT00588731
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCT00690274
View directory record Official record
Conditions
Schizophrenia
Interventions
BF2.649, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

NCT00374920
View directory record Official record
Conditions
Bipolar Disorder With Manic or Mixed Episodes
Interventions
MEM 1003
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 4 Interventional

Risperidone Augmentation in Patients With Schizophrenia

NCT00289861
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747
View directory record Official record
Conditions
Schizophrenia
Interventions
Transdermal Nicotine Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

NCT02118610
View directory record Official record
Conditions
Schizophrenia
Interventions
L-tetrahydropalmatine (30mg), Sugar pill
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 4 Interventional

Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse

NCT00223197
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Substance Abuse
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 8, 2026, 10:23 PM EDT
Completed Phase 4 Interventional

Antidepressant Therapy for Bipolar II Major Depression

NCT00641927
View directory record Official record
Conditions
Bipolar Type II Disorder
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
Stanley Medical Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 8, 2026, 10:23 PM EDT